Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice

• Published in: International journal of molecular sciences 2022-11, Vol.23 (21), p.13478
• Main Authors: Rao, Huanan, Song, Xiaominting, Lei, Jieting, Lu, Peng, Zhao, Guiying, Kang, Xin, Zhang, Duanna, Zhang, Tingrui, Ren, Yali, Peng, Cheng, Li, Yuzhi, Pei, Jin, Cao, Zhixing
• Format: Article
• Language: English
• Subjects: Antigens; Bacteria; Bacterial infections; Bronchus; Bruton's tyrosine kinase; Computed tomography; Coronaviruses; COVID-19; Cytokines; Edema; Enzyme-linked immunosorbent assay; Epidermal growth factor receptors; Evaluation; Flow cytometry; Gram-negative bacteria; Gram-positive bacteria; IL-1β; Immunofluorescence; Immunohistochemistry; Infections; Inflammation; Inhibitor drugs; Injury prevention; Interleukin 6; Kinases; Lavage; Leukocytes (neutrophilic); Lipopolysaccharides; Lungs; Lymphocytes; Neutrophils; NF-κB protein; Pandemics; Polyinosinic:polycytidylic acid; Protein-tyrosine kinase; Proteins; Severe acute respiratory syndrome coronavirus 2; Signal transduction; Tomography; Trachea; Tumor necrosis factor-α; Tyrosine; Viral infections; Western blotting; γ-Interferon
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232113478

Ibrutinib has potential therapeutic or protective effects against viral- and bacterial-induced acute lung injury (ALI), likely by modulating the Bruton tyrosine kinase (BTK) signaling pathway. However, ibrutinib has multi-target effects. Moreover, immunity and inflammation targets in ALI treatment are poorly defined. We investigated whether the BTK-, FLT3-, and EGFR-related signaling pathways mediated the protective effects of ibrutinib on ALI. The intratracheal administration of poly I:C or LPS after ibrutinib administration in mice was performed by gavage. The pathological conditions of the lungs were assessed by micro-CT and HE staining. The levels of neutrophils, lymphocytes, and related inflammatory factors in the lungs were evaluated by ELISA, flow cytometry, immunohistochemistry, and immunofluorescence. Finally, the expression of proteins associated with the BTK-, FLT3-, and EGFR-related signaling pathways were evaluated by Western blotting. Ibrutinib (10 mg/kg) protected against poly I:C-induced (5 mg/kg) and LPS-induced (5 mg/kg) lung inflammation. The wet/dry weight ratio (W/D) and total proteins in the bronchoalveolar lavage fluid (BALF) were markedly reduced after ibrutinib (10 mg/kg) treatment, relative to the poly I:C- and LPS-treated groups. The levels of ALI indicators (NFκB, IL-1β, IL-6, TNF-α, IFN-γ, neutrophils, and lymphocytes) were significantly reduced after treatment. Accordingly, ibrutinib inhibited the poly I:C- and LPS-induced BTK-, FLT3-, and EGFR-related pathway activations. Ibrutinib inhibited poly I:C- and LPS-induced acute lung injury, and this may be due to its ability to suppress the BTK-, FLT3-, and EGFR-related signaling pathways. Therefore, ibrutinib is a potential protective agent for regulating immunity and inflammation in poly I:C- and LPS-induced ALI.